Innovent Biologics (suzhou) Co. Ltd.

This early-phase study tests a new drug called IBI363 in about 40 people with advanced solid tumors or lymphomas that haven't responded to other treatments. The main goal is to find the safest dose and check for side effects. Researchers will also measure how the drug moves throu…

This study tests whether a new medicine called IBI362 works better than semaglutide (a known weight-loss drug) for Chinese adults who are overweight and have a fatty liver. About 479 people will receive weekly injections for 48 weeks. The main goals are to see how much weight and…

This study tests whether giving two immunotherapy drugs (IBI310 and sintilimab) before surgery can eliminate or shrink tumors in people with a specific genetic type of colon cancer (MSI-H/dMMR). About 453 adults with stage IIB or III colon cancer that can be surgically removed wi…

This phase 3 study tests a new drug called IBI343 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has not responded to prior therapies. The trial includes 464 participants whose tumors have a specific marker (CLDN18.2) and lac…

This early-stage study tests the safety and how the body handles a single dose of IBI3033 in 32 healthy Chinese adults. Participants receive either the drug or a placebo and are monitored for side effects and drug levels over 12 weeks. The goal is to gather safety data, not to tr…

This study checks if a new drug called IBI3027 works the same as the approved drug Dupixent in healthy Chinese men. 180 volunteers will get a single shot of either drug and be monitored for 56 days. The goal is to see if the new drug is safe and reaches similar levels in the body…